Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021
NEW YORK, July 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021
http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali
How will events this decade affect those activities?
How will the pharma wholesale and distribution industry perform from 2011 onwards? Our new report shows you that industry and market's revenue potential from 2011 to 2021.
There, you will assess the trends and opportunities shaping the pharmaceutical distribution chain. We aim to save you time and aid your decisions through our research, analysis and discussions.
Our report shows you revenue prospects for pharmaceutical wholesale and distribution activities at total world, company and national levels.
We forecast revenues of McKesson (US), Cardinal Health (US), AmerisourceBergen (US), The Phoenix Group (Europe), Celesio (Europe), Alfresa Holdings (Japan), Medipal (Japan), Alliance Boots (Europe) and Suzuken (Japan). You will discover their prospects to 2021.
What effects will healthcare budget cuts have on pharmaceutical wholesalers? Which national markets will provide the best opportunities from 2011 to 2021? How common will direct-to-pharmacy distribution become? Our work provides answers you need.
We help you to assess the pharma wholesale and distribution industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where the industry and market are heading.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies and external opinions from our industry survey.
We include 117 tables and charts and two research interviews (shown in the accompanying lists). Our study helps you to understand pharma wholesaling and distribution this decade.
Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
• You will receive hard data for the pharmaceutical wholesale and distribution industry and market from 2009 to 2021
• You will discover revenue forecasting for the overall world market from 2011 to 2021
• You will assess leading companies in the pharma distribution chain, discovering their activities, potential revenue values and commercial outlooks to 2021
• You will find revenue predictions for leading geographical markets to 2021 (US, Japan, China, Germany, France, UK, Spain, Italy, Brazil and Russia)
• You will investigate competition and opportunities that will influence revenues
• You will see what will stimulate and restrain the industry and market
• You will view opinion from our survey, including full interview transcripts.
That mix of quantitative and qualitative market analysis sets our report apart. Our independent analysis helps you to stay ahead in commercial knowledge.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in pharmaceutical wholesaling and distribution. We give predictions and answers you need. Don't miss out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Table of Contents
1. Executive Summary
1.1 Overview of the Study
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. Introduction to the Industry and Market
2.1 The Role of Pharmaceutical Wholesalers
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy
2.2.3 Pharmacy Benefit Managers
2.3 Generating Revenue and Profit
2.3.1 Forward Buying
2.3.2 Fee-for-Service
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback
2.3.6 Parallel Trade
3. The World Pharmaceutical Wholesale and Distribution Market 2011-2021
3.1 The World Market in 2009
3.2 World Market Forecast 2011-2021
3.3 The US
3.3.1 An Increase in Fee-for-Service Activity
3.3.2 US Market Forecast 2011-2021
3.4 Europe
3.4.1 Differences between the US and Europe
3.4.1.1 State-Funded Healthcare and Reimbursement
3.4.2 European Market Forecast 2011-2021
3.4.3 Germany
3.4.3.1 Healthcare Reform
3.4.3.2 Market Forecast 2011-2021
3.4.4 France
3.4.4.1 Market Forecast 2011-2021
3.4.5 Spain
3.4.5.1 Market Forecast 2011-2021
3.4.6 The UK
3.4.6.1 Price Cuts 2009-2010
3.4.6.2 Market Forecast 2011-2021
3.4.7 Italy
3.4.7.1 Market Forecast 2011-2021
3.5 Japan
3.5.1 Drug Pricing and Performance Fees
3.5.2 Market Forecast 2011-2021
3.6 China
3.6.1 Leading Companies 2009-2010
3.6.2 Recent Market Developments
3.6.3 Market Forecast 2011-2021
3.7 Brazil
3.7.1 Leading Companies 2009-2010
3.7.2 Market Forecast 2011-2021
3.8 Russia
3.8.1 Market Trends
3.8.2 Market Forecast 2011-2021
3.9 Regional Market Shares 2011-2021
4. Leading Wholesalers in the Global Market 2011-2021
4.1 Revenue vs. Profit
4.1.1 Profit Margins 2009
4.2 Leading Companies Market Forecast 2011-2021
4.3 McKesson
4.3.1 Recent Performance
4.3.2 Future Strategies
4.3.3 Revenue Forecast 2011-2021
4.4 Cardinal Health
4.4.1 Segment Reorganisation
4.4.2 Recent Performance
4.4.3 Future Strategies
4.4.4 Revenue Forecast 2011-2021
4.5 AmerisourceBergen
4.5.1 Recent Performance
4.5.2 Future Strategies
4.5.3 Revenue Forecast 2011-2021
4.6 The Phoenix Group
4.6.1 Recent Performance
4.6.2 The Tamro Group 2009-2010
4.6.3 Future Strategies
4.6.4 Revenue Forecast 2011-2021
4.7 Celesio
4.7.1 Recent Performance
4.7.2 Future Strategies
4.7.3 Revenue Forecast 2011-2021
4.8 Alfresa Holdings
4.8.1 Recent Performance
4.8.2 Future Strategies
4.8.3 Revenue Forecast 2011-2021
4.9 Medipal
4.9.1 Recent Performance
4.9.2 Future Strategies
4.9.3 Revenue Forecast 2011-2021
4.10 Alliance Boots
4.10.1 Recent Performance
4.10.2 Future Strategies
4.10.3 Revenue Forecast 2011-2021
4.11 Suzuken
4.11.1 Recent Performance
4.11.2 Future Strategies
4.11.3 Revenue Forecast 2011-2021
5. Qualitative Analysis of the Market 2011-2021
5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market 2011-2021
5.2 Strengths
5.2.1 Large Companies Dominate the Market
5.2.2 Wholesalers Do More than Deliver Drugs
5.2.2.1 Pre-Wholesaling
5.3 Weaknesses
5.3.1 Counterfeiting
5.3.2 Low Margins
5.4 Opportunities
5.4.1 Increased Demand for Pharmaceuticals
5.4.2 Generics
5.4.3 Globalisation
5.5 Threats
5.5.1 Direct-to-Pharmacy (DTP)
5.5.1.1 DTP in Europe
5.5.1.2 The UK
5.5.1.3 Poland
5.5.1.4 DTP in Australia
5.5.1.5 Further Expansion
5.5.2 Healthcare Budget Cuts
5.5.3 Diversion and Re-importation
5.5.4 Supermarket Pharmacies
5.5.4.1 Case Study: Walmart
6. Pharmaceutical Wholesale Industry Trends 2011-2021
6.1 Combating Counterfeit Medicines
6.1.1 The US and E-Pedigree
6.1.2 European Pedigree Legislation
6.1.3 Anti-Counterfeiting Strategies in Other Markets
6.1.4 Issues in Serialisation for Wholesalers
6.2 Growth in Specialty Pharmaceuticals
6.3 Industry Consolidation
6.4 Chain Pharmacies and Vertical Integration
7. Opinions from Our Survey
7.1 Professor David Taylor, Professor of Pharmaceutical and Public Health Policy, University of London
7.1.1 The Purpose of DTP
7.1.2 The Impact of DTP on Pharmacies
7.1.3 Changes to Drug Pricing in the UK
7.1.4 DTP and the Patient
7.1.5 Wholesale Trends Across Europe
7.2 Dr Heinz Kobelt, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC)
7.2.1 Benefits of Parallel Trade
7.2.2 Generics and Parallel Trade
7.2.3 Parallel Traders Combating Counterfeiting
7.2.4 The DTP Model
8. Conclusions
8.1 There Will Be Steady Growth in Developed Markets
8.1.1 Generics Will Threaten Revenues
8.1.2 Manufacturers Will Deliver Direct More Regularly
8.1.3 There Will Be Greater Demand for Specialty Medicines
8.2 Growth Will Be Faster in Emerging Markets
8.2.1 Consolidation Will Drive Growth
8.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
List of Tables
Table 2.1 Prevalence of the DTP Model in the UK, 2011
Table 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009
Table 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021
Table 3.3 Global Market Drivers and Restraints, 2011-2021
Table 3.4 US Pharmaceutical Wholesale and Distribution Market by Company, 2009
Table 3.5 US Market Drivers and Restraints, 2011-2021
Table 3.6 European Pharmaceutical Wholesale and Distribution Market by Country, 2009
Table 3.7 How Price Controls Vary Across Europe, 2010
Table 3.8 European Market Drivers and Restraints, 2011-2021
Table 3.9 European Pharmaceutical Wholesale Market Forecast, 2009-2021
Table 3.10 German Market Drivers and Restraints, 2011-2021
Table 3.11 French Market Drivers and Restraints, 2011-2021
Table 3.12 Spanish Market Drivers and Restraints, 2011-2021
Table 3.13 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009
Table 3.14 UK Market Drivers and Restraints, 2011-2021
Table 3.15 Italian Market Drivers and Restraints, 2011-2021
Table 3.16 Japanese Points of Delivery, 2011
Table 3.17 Japanese Pharmaceutical Wholesale and Distribution Market, 2009
Table 3.18 Global Population Aged Over 65, 2009-2025
Table 3.19 Japanese Market Drivers and Restraints, 2011-2021
Table 3.20 Chinese Market Drivers and Restraints, 2011-2021
Table 3.21 Brazilian Market Drivers and Restraints, 2011-2021
Table 3.22 Russian Pharmaceutical Wholesale and Distribution Market, 2009
Table 3.23 Russian Market Drivers and Restraints, 2011-2021
Table 4.1 Leading Companies in the Market, 2009
Table 4.2 Company Year End Revenues, 2009
Table 4.3 Profit Margins Reported by Leading Companies, 2009
Table 4.4 Market Leaders: Drivers and Restraints, 2011-2021
Table 4.5 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021
Table 4.6 McKesson Pharmaceutical Wholesale Revenue by Country, 2009
Table 4.7 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009
Table 4.8 McKesson Wholesale Revenue Forecast, 2009-2021
Table 4.9 Cardinal Health's Bulk and Non-bulk Orders, 2009-2010
Table 4.10 Cardinal Health Wholesale Revenue Forecast, 2009-2021
Table 4.11 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit by Quarter, 2009
Table 4.12 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit, Q1-Q3 2010
Table 4.13 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021
Table 4.14 The Phoenix Group Wholesale Subsidiaries, 2010
Table 4.15 The Phoenix Group Revenue and Gross Profit, February-October 2009-2010
Table 4.16 Tamro Group Revenue, 2009-2010
Table 4.17 The Phoenix Group Wholesale Revenue Forecast, 2009-2021
Table 4.18 Celesio Wholesale Subsidiaries, 2010
Table 4.19 Celesio Wholesale Revenue by Country, 2009
Table 4.20 Celesio Wholesale Revenue Forecast, 2009-2021
Table 4.21 Alfresa Wholesale Subsidiaries, 2010
Table 4.22 Alfresa Wholesale Revenue and Operating Income by Quarter, 2009
Table 4.23 Alfresa Wholesale Revenue Forecast, 2009-2021
Table 4.24 Medipal Wholesale Revenue and Operating Income by Quarter, 2009
Table 4.25 Medipal Wholesale Revenue and Operating Income, Q1-Q3 2010
Table 4.26 Medipal Wholesale Revenue Forecast, 2009-2021
Table 4.27 Alliance Boots Wholesale Revenue by Country, 2009
Table 4.28 Alliance Boots Wholesale Revenue Forecast, 2009-2021
Table 4.29 Suzuken Wholesale Revenue and Operating Income by Quarter, 2009
Table 4.30 Suzuken Wholesale Revenue and Operating Income, Q1-Q3 2010
Table 4.31 Suzuken Wholesale Revenue Forecast, 2009-2021
Table 5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market, 2011-2021
Table 5.2 Revenues for Leading Wholesalers and Manufacturers, 2009
Table 5.3 Regional Split of Counterfeiting Incidents, 2009
Table 5.4 Global Recorded Incidents of Counterfeit Medicines, 2002-2009
Table 5.5 Strengths and Weaknesses of the DTP Model
Table 8.1 Global Pharmaceutical Wholesale Market Shares by Country, 2009, 2015 and 2021
Table 8.2 US Patent Expiries for Leading Small Molecule Drugs, 2010-2012
List of Figures
Figure 2.1 Traditional Routes of Drug Distribution, 2011
Figure 2.2 CVS Caremark Revenue by Segment, 2009
Figure 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009
Figure 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.3 US Pharmaceutical Wholesale and Distribution Market by Company, 2009
Figure 3.4 US Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.5 European Pharmaceutical Wholesale and Distribution Market by Country, 2009
Figure 3.6 European Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.7 German Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.8 French Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.9 Spanish Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.10 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009
Figure 3.11 UK Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.12 Italian Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.13 Japanese Points of Delivery, 2011
Figure 3.14 Japanese Pharmaceutical Wholesale and Distribution Market, 2009
Figure 3.15 Changes to Japanese Drug Pricing, 2010
Figure 3.16 Aging Global Population, 2009-2025
Figure 3.17 Japanese Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.18 Chinese Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.19 Brazilian Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.20 Russian Pharmaceutical Wholesale and Distribution Market, 2009
Figure 3.21 Russian Pharmaceutical Wholesale Market Forecast, 2009-2021
Figure 3.22 Global Pharmaceutical Wholesale and Distribution Market by Country, 2015
Figure 3.23 Global Pharmaceutical Wholesale and Distribution Market by Country, 2021
Figure 4.1 Leading Companies in the Market, 2009
Figure 4.2 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021
Figure 4.3 McKesson Pharmaceutical Wholesale Revenue by Country, 2009
Figure 4.4 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009
Figure 4.5 McKesson Wholesale Revenue Forecast, 2009-2021
Figure 4.6 Cardinal Health Pharmaceutical Revenue by Company, FY 2009-2010
Figure 4.7 Cardinal Health's Bulk and Non-bulk Orders, FY 2009-2010
Figure 4.8 Cardinal Health Wholesale Revenue Forecast, 2009-2021
Figure 4.9 AmerisourceBergen Pharmaceutical Distribution Revenue by Quarter, 2009
Figure 4.10 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021
Figure 4.11 The Phoenix Group Wholesale Revenue, February-October 2009-2010
Figure 4.12 Tamro Group Revenue, 2009-2010
Figure 4.13 The Phoenix Group Wholesale Revenue Forecast, 2009-2021
Figure 4.14 Celesio Wholesale Revenue by Country, 2009
Figure 4.15 Celesio Wholesale Revenue Forecast, 2009-2021
Figure 4.16 Alfresa Wholesale Operating Income Margin by Quarter, 2009
Figure 4.17 Alfresa Wholesale Revenue Forecast, 2009-2021
Figure 4.18 Medipal Wholesale Revenue by Quarter, 2009
Figure 4.19 Medipal Wholesale Operating Income Margin, Q1-Q3 2009-2010
Figure 4.20 Medipal Wholesale Revenue Forecast, 2009-2021
Figure 4.21 Alliance Boots Wholesale Revenue by Country, 2009
Figure 4.22 Alliance Boots Wholesale Revenue Forecast, 2009-2021
Figure 4.23 Suzuken Wholesale Revenue by Quarter, 2009
Figure 4.24 Suzuken Wholesale Operating Income Margin, Q1-Q3 2010
Figure 4.25 Suzuken Wholesale Revenue Forecast, 2009-2021
Figure 5.1 Revenues for Leading Wholesalers and Manufacturers, 2009
Figure 5.2 Regional Split of Counterfeiting Incidents, 2009
Figure 5.3 Global Recorded Incidents of Counterfeit Medicines, 2002-2009
Figure 5.4 Comparison of the Wholesaler and Direct-to-Pharmacy Routes
Figure 6.1 Anti-Counterfeiting Strategies in the US and Europe, 2011
Companies Listed
Acofarma (Asociación Cooperativas Farmacéuticas) [Spain]
Alfresa Holdings and its subsidiaries:
Alfresa
Alfresa Medical Service
Alfresa Nikken Sangyo
Ando Co
CS Yakuhin Co
Kowa Pharmaceuticals Co
Meisho Co
Odashima
Ryuyaku Co
Seiwa Sangyo Co
Shikoku Alfresa
Alliance Boots and its subsidiaries:
Alliance Healthcare
Alloga
Almus Pharmaceuticals
Andreae-Noris Zahn (ANZAG) [Germany]
Cordia Healthcare
Galenica
Hedef Alliance Holding
HydraPharm [Algeria]
Megapharm [Germany]
UCP [Egypt]
AmerisourceBergen and its subsidiaries:
American Health Packaging
Anderson Packaging
Brecon Pharmaceuticals
Astellas Pharma
AstraZeneca
Athos Farma
Australian Pharmaceutical Industries
Barr Pharmaceuticals (now part of Teva Pharmaceuticals)
Bayer
Bristol-Myers Squibb
British Association of Pharmaceutical Wholesalers (BAPW)
Bundesverband des Pharmazeutischen Grosshandel (PHAGRO) [Germany]
Cardinal Health and its subsidiaries:
Kinray
MediCap Pharmacy
Medicine Shoppe International
Zuellig Pharma China (Yong Yu)
CareFusion
Celesio and its subsidiaries:
AAH Pharmaceuticals [UK]
Admenta Italia [Italy]
Cahill May Roberts [Ireland]
Evolution Homecare [UK]
GEHE [Germany]
GEHE Pharma Praha [Czech Republic]
Herba Chemosan [Austria]
Inten [Germany]
Kemofarmacija [Slovenia]
Laboratoria Flandria [Belgium]
Norsk Medisinaldepot [Norway]
OCP [France/Portugal]
Panpharma [Brazil]
Pharma Belgium [Belgium]
Pharmactiv [France]
Tjellesen Max Jenne [Denmark]
Vitapharm [Slovenia]
Center for Medicine in the Public Interest [US]
CERP France (CERP Bretagne Nord, CERP Rhin Rhone Mediterranee and CERP Rouen)
Chambre Syndicale de la Répartition Pharmaceutique (CSRP) [France]
China Health Systems
China National Pharmaceutical Group (Sinopharm)
Cofares Hefame (formerly Cofares and Hefame)
CVS Caremark (formerly CVS and Caremark Rx)
Department of Health [UK]
Eli Lilly
European Association of Euro-Pharmaceutical Companies (EAEPC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
GlaxoSmithKline (GSK)
Guangzhou Pharmaceuticals
Healthcare Distribution Management Association (HDMA) [US]
Hubei Kyoso Pharmaceutical (a Toho and Jointown joint venture)
Humana
Johnson & Johnson (J&J)
Japanese Pharmaceutical Wholesalers Association (JPWA)
Jointown Pharmaceutical Group
Katren
KL Holding
Kohlberg Kravis Roberts & Co (KKR)
McKesson and its subsidiaries:
Nadro
Oncology Therapeutics Network
Parata Systems
US Oncology
Medco Health Solutions
Medipal and its subsidiaries:
Atol Co
Chiyaku Co
Everlth Co
Izutsu Pharmaceutical Co
Kobashou Co
Kuraya Sanseido (now Mediceo)
Heisei Yakuhin Co
Nakagawa Seikodo Co
Sinopharm Medicine Holding Beijing Huahong
Ushioda Sagokudo Yakuhin Co
Ministry of Commerce [China]
Mitsubishi
Napp Pharmaceutical Group
National Association of Boards of Pharmacy (NABP) [US]
National Health Service (NHS) [UK]
Novartis
Novo Nordisk
Pfizer
Pharmaceutical Security Institute (PSI) [US]
Polish Pharmaceutical Chamber
Polska Grupa Farmaceutyczna
Profarma
Prosper
Protek
ratiopharm
Rite-Aid
Roche
Rosta Pharmaceutical Group
Sanacorp
sanofi-aventis
Shanghai Pharmaceutical Group
SIA International
Sigma Pharmaceuticals
Sincamesp [Brazil]
State Food and Drug Administration (SFDA) [China]
Suzuken and its subsidiaries:
Astis Co
Jingu Yakuhin Co
Nakano Yakuhin Co
Sanki
Shanghai Suzuken Huzhong Pharmaceutical
Shoyaku Co
Suzuken Iwate Co
Suzuken Okinawa Yakuhin Co
Target
Teva Pharmaceuticals
The Phoenix Group and its subsidiaries:
Amedis-UE [Switzerland]
Apokjeden Group [Norway]
Brocacef Holding [The Netherlands]
Gruppo Comifar [Italy]
Libra [Bulgaria]
Nomeco [Denmark]
Numark [UK]
Phoenix Arzeiwarengro?handlung [Austria]
Phoenix Farmacija [Croatia]
Phoenix Lékárensky [Czech Republic]
Phoenix Healthcare Distribution [UK]
Phoenix Pharma [France/Hungary/Serbia]
Phoenix Pharma Polska [Poland]
Phoenix Pharmahandel [Germany]
Phoenix Zdravotnícke zasobovanie [Slovakia]
Rowlands [UK]
Tamro [Sweden]
SIA Tamro [Latvia]
Tamro Suomi [Finland]
Tamro Eesti [Estonia]
UAB Tamro [Lithuania]
Toho Holdings
Torfarm
United Nations (UN)
Walgreens
Walmart
Wyeth Pharmaceuticals (now part of Pfizer)
To order this report:
Wholesaling Industry: Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021
Wholesaling Business News
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article